Wed, Aug 20, 2014, 12:54 AM EDT - U.S. Markets open in 8 hrs 36 mins


% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

  • rumpot71 rumpot71 Sep 11, 2012 9:59 PM Flag

    Any other physicians here?

    Or seasoned biotech investors? PhDs?

    I am very impressed with the technology here and very optimistic about its broad applications. I think it is a no brainer long-term buy and could become a multi-billion dollar company once tubulysin gets going and if they have success in the autoimmune markets. I just wanted to see if anyone shared the optimism here.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ecyt will be game changer, with personalized approach anf smdc platform, potential of EC145, in all treatments, just FR++ is over 1.000.000 patients, tubulysin, might be alternate anf huge in potential; game changer of the BIO industry, like Google in 2001

      I am not a BIO PHD, but checked over 200 BIO companies, only invested in MDVN, which I left at $80, liked it, but now overpriced, Endocyte has much more potential and Merck (as well as ECYT) will be the players, it is not about Ovarian, it is total picture and roll-out on all kind on FR++ (probably also FR+) cancer expressed types

      This is no a billion market, but make a 50-70-billion market in the end.

      One other gesture from Merck is that ECYT is getting on the map with Physicians!

    • sunshinecamesoftly2002 sunshinecamesoftly2002 Sep 11, 2012 11:34 PM Flag

      I am an MD and biochemist. Antifolate treatment is a cornerstone of treatment in oncology and ECYT platform is the most powerful around to date. It has the possibility of being completely disruptive of present treatment models.
      There are competitors with monoclonals to folate receptors (inlude ROCHE) but I think the SMDC are a better model and ECYT new drug tubulysin may be a game changer. I have a big wager here and think it has the potential of ARIA which has been my most successful investment so far.

      Sentiment: Buy

6.65-0.05(-0.75%)Aug 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.